Statin use is associated with reduced mortality after respiratory viral infection
| Autor: | Óscar González-Lorenzo, Ana Rodriguez, Ana María Pello-Lázaro, Borja Ibanez, Álvaro Aceña, José Tuñón, Andrea María Kallmeyer Mayor, Maria De Los Angeles Zambrano Chacon, Ricardo Fernández Roblas, Juan Antonio Franco-Peláez, Felipe Villar Álvarez, Laura Esteban-Lucía, Camila Sofia García-Talavera, Luis Nieto Roca |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Pulmonary and Respiratory Medicine
medicine.medical_specialty Statin medicine.drug_class Population lcsh:Medicine Disease 030204 cardiovascular system & hematology 03 medical and health sciences 0302 clinical medicine Internal medicine medicine cardiovascular diseases 030212 general & internal medicine education education.field_of_study business.industry Proportional hazards model Respiratory viral infection lcsh:R nutritional and metabolic diseases Retrospective cohort study Original Articles Statin treatment Respiratory Infections lipids (amino acids peptides and proteins) Observational study business |
| Zdroj: | ERJ Open Research article-version (VoR) Version of Record ERJ Open Research, Vol 7, Iss 1 (2021) |
| ISSN: | 2312-0541 |
| DOI: | 10.1183/23120541.00365-2020 |
| Popis: | Background Several studies suggest that statins, besides reducing cardiovascular disease, have anti-inflammatory properties which might provide a benefit in downregulating the immune response after a respiratory viral infection (RVI) and, hence, decreasing subsequent complications. We aim to analyse the effect of statins on mortality after RVI. Methods A single-centre, observational and retrospective study was carried out including all adult patients with a RVI confirmed by PCR tests from October 2, 2017 to May 20, 2018. Patients were divided between statin users and non-statin users and followed-up for 1 year, and all causes of death were recorded. In order to analyse the effect of statin treatment on mortality after RVI we planned two different approaches, a multivariate Cox regression model with the overall population and a univariate Cox model with a propensity-score matched population. Results We included 448 patients, 154 (34.4%) of whom were under statin treatment. Statin users had a worse clinical profile (older population with more comorbidities). During the 1-year follow-up, 67 patients died, 17 (11.0%) in the statin group and 50 (17.1%) in the non-statin group. Multivariate Cox analysis showed that statins were associated with mortality benefit (HR 0.47, 95% CI 0.26–0.83; p=0.01). In a matched population (101 statins users and 101 non-statins users) statins also remained associated with mortality benefit (HR 0.32, 95% CI 0.14–0.72; p=0.006). Differences were mainly driven by non-cardiovascular mortality (HR 0.31, 95% CI 0.13–0.73; p=0.004). Conclusions Chronic statin treatment was associated with reduced 1-year mortality in patients with laboratory-confirmed RVI. Further studies are needed to determine the exact role of statin therapy after RVI. Statin treatment is associated with reduced 1-year mortality after respiratory viral infections, despite the higher risk profile of patients on statins. Statins seem a good candidate to be tested during the current global pandemic. https://bit.ly/36t0tDh |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|